Baxalta Gmbh

3b Pharmaceuticals Gmbh

Scil Proteins Gmbh

Shire Orphan Therapies Gmbh

Jerini Ag

Matthias Paschke

Frank Osterkamp

Ulrich Reineke

Friedrich Scheiflinger

Michael Dockal

Thomas Polakowski

Rudolf Hartmann

Christian Haase

Christiane Smerling

Bettina Hartlieb

Ulf Reimer

Gerd Hummel

Uwe Richter

Dirk Scharn

Christoph Gibson

Dirk Zboralski

Karsten Schnatbaum

Elsa Locardi

Jan Ungewiß

Thomas Tradler

Jochen Pfeifer

Eberhard Schneider

Aileen Höhne

Anne Bredenbeck

Jan Ungewiss

The present invention is related to a compound comprising a cyclic peptide and a chelator, and its use.

Compounds comprising a fibroblast activation protein ligand and use thereof

The present invention is related to a conjugate comprising a structure of general formula (1) [TM1]-[AD1]-[LM]-[AD2]-[TM2] (1), wherein TM1 is a first targeting moiety, wherein the first targeting moiety is capable of binding to a first target, AD1 is a first adapter moiety or is absent, LM is a linker moiety or is absent, AD2 is a second adapter moiety or is absent, and TM2 is a second targeting moiety, wherein the second targeting moiety is capable of binding to a second target; wherein the first targeting moiety and/or the second targeting moiety is a compound of formula (2): wherein Ris selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2 adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.1]nonane-9 carboxylic acid; Ris selected from the group consisting of (C-C)alkyl, (C-C)cycloalkyl, (CC)cycloalkylmethyl, halogen, nitro and trifluoromethyl; ALK' is (C-C)alkylidene; R, Rand Rare each and independently selected from the group consisting of hydrogen and (C-C)alkyl under the proviso that one of R, Rand Ris of the following formula (3) wherein ALK&#x2032; is (C-C)alkylidene; Ris selected from the group consisting of hydrogen and (C-C)alkyl; and Ris a bond; or a pharmacologically acceptable salt, solvate or hydrate thereof. 

Conjugate comprising a neurotensin receptor ligand and use thereof

The invention provides peptides, including peptides that bind and, optionally, inhibit Protein S, and compositions thereof. The peptides may be used to, e.g., inhibit Protein S activity, enhance thrombin formation in a subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify Protein S, and identify a Protein S binding compound.

Peptides and methods of use

The present invention concerns a protein mixture comprising at least a first fusion protein comprising a protein or protein fragment, and an interaction domain and a protein translocation sequence, which effects that the fusion protein upon expression in a bacterium is translocated through the cytoplasmic membrane in an essentially unfolded state and at least a second fusion protein comprising a protein or protein fragment, and an interaction domain and a protein translocation sequence which effects that the fusion protein is translocated through the cytoplasmic membrane upon expression in a bacterium in an essentially folded state, wherein the interaction domain of the first protein can bind to those of the second protein.

Mixture of at least two fusion proteins, the production thereof and the use of the same

The present invention is related to compound of the formula (I): or a pharmacologically acceptable salt, solvate, or hydrate thereof, wherein A is a 6-membered heteroaryl having from 1 to 3 heteroatoms, each independently selected from N or O and the other substituents are defined as in the claims. 

8-oxy-quinoline derivatives as bradykinin B2 receptor modulators

Growing community of inventors

Berlin, Germany

Matthias Paschke